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Abstract
Botulinum toxin A (BTX-A) is widely used worldwide to overcome the significant prob-
lem in spastic cerebral palsy (CP). In the past three decades, botulinum toxin serotype 
A (BTX-A) has been introduced as a selective treatment option for spasticity in children 
with cerebral palsy. BTX-A is an acetylcholine-blocking agent that causes presynaptic 
neuromuscular blocking when injected into the muscle. Its action of decreasing or nor-
malization of tone prevent the development of contractures and deformities and avoid 
or postponed surgical intervention particularly when combined with other treatment 
modalities such as physiotherapy, casting, orthosis, etc. Equinus deformity, scissoring 
and crouch gait in the lower limbs, and different spastic deformities like pronation of 
forearm, elbow flexion, wrist flexion, fisting, or abnormal dystonic posture of upper limb 
deformities were the main indications wherein botulinum toxin injection is needed in 
spastic cerebral palsy; moreover, its benefit of relieving pain that are associated with 
muscular hypertonia and palpation of the muscle, particularly the large one, remains the 
cornerstone for injection of BTX in CP patient for most experts worldwide, but it needs 
a well of knowledge in anatomy and its landmark. Invasive procedure like electromy-
ography (EMG) is more difficult to be applied successfully in children than in adults. 
Spasticity is considered a positive phase of muscle function. Therefore, when relaxing 
the muscle, the patient’s condition might get worse functionally in some instance. So, the 
first question clinician put in his account before injecting BTX is whether hypertonia is 
impeding or improving function; therefore, injection is tailored individually by an expert 
physician. Generally, the adverse side effects of BTX-A are seldom to occur providing 
that the physician strictly adheres to the dose ranges and reinjection period. The inter-
injection period must be at least 12 weeks to avoid antibodies ands. So far, BTX-A is 
considered to be safe to some extent if used professionally; however, long-term adverse 
effect particularly with multilevel therapy are still not clear.
Keywords: cerebral palsy, botulinum toxin, spasticity, muscle function, children
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Cerebral palsy (CP) is a nonprogressive encephalopathy that primarily affects motor system; 
in consequence, there is a defect in motor milestone development with a variable degree 
of severity and locomotor deformities. Therefore, CP is a complex entity with known and 
unknown causes [1].
Cerebral palsy (CP) is the most frequent cause of spasticity in children [2]. In the last 25 years, 
injecting botulinum toxin type A (BTX-A) has been proven as an effective medicine strategy 
to decrease hypertonia in CP child. Now used in most countries of five continents, it is a 
green light after 2 years of age adopted by most expertise; however, there is big difference in 
licensing from one country to another. Therefore, most of BTX-A use is labeled according to 
its trademark. Nowadays, BTX-A has a major role of the multidisciplinary treatment in spas-
tic CP, in addition to physiotherapy, occupational therapy, speech therapy, casting, ankle-
foot orthoses (AFO), and knee-ankle-foot orthosis (KAFO) surgical application of intrathecal 
baclofen; selective dorsal rhizotomy (SDR); and different orthopedic interventions, with vary-
ing simple to complex intervention to achieve optimal reconstructive [3].
Within the current clinical management of CP in children, the use of BTX-A is recommended 
to improve function and to support motor development [4]. Botulinum toxin injection has an 
additional role on the decrease of pain associated with focal spasticity [5]. Actually, in muscu-
lar hypertonia, sever muscle contraction produces compromising vessel resulting in ischemia, 
ultimately agonizing nociceptive pain (ischemic muscular pain). Nevertheless, decrease of 
spasm by BTX injection improved blood flow, the ischemia markedly decreased, and pain 
subsided by muscular relaxation effect of BTX [6].
BTX had been discovered at the beginning of the nineteenth century as a poison. This poison 
is a protein, which is a product of Clostridium botulinum bacterium, a Gram-positive anaerobe. 
Meat is considered the primary source of this bacterium, from the name “botulus” which 
mean sausage, though it is present in different food types. The German physician Justinus 
Kerner in 1818 first wrote about poison that food-borne diseases who was described confi-
dently in the middle-aged patient. The features of botulism have been known since ancient 
times around the time of Christ [7]. He then published a monograph on poisoning in 1820 in 
which he described the features, made many original observations, and commented on the 
possible causation, diagnosis, and treatment [8]. He concluded that a toxin produced by an 
infective agent was responsible for the features of paralysis of skeletal and smooth muscles. 
He published a second monograph in 1822, in which he laid out his hypotheses on BTX and 
described clinical evaluation of the problem through case histories of his patients and through 
post-mortem examination of patients with botulism [9].
1.1. Physiology of neuromuscular transmission
When we take neuromuscular junction (NMJ) in focus, it consists of the terminal branch of the 
motor neuron and the muscle fiber that innervates and synaptic cleft between. Acetylcholine 
is synthesized and stored in the synaptic vesicles that are released into the synaptic cleft by 
fusion with the presynaptic membrane, through the process called exocytosis. The process of 
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exocytosis is a result of a nerve action potential arriving at the terminal membrane causing 
an influx of calcium ions through voltage-dependent channel and binding to the receptors 
on the postsynaptic neuron, causing a change in the electrical properties of that membrane, 
which finally results in the contraction of the muscle fiber. Calcium regulated the process of 
exocytosis which is considered a complicated process that involves the actions of proteins 
located on the vesicles in the cytosol and on the presynaptic membrane. The protein known 
as synapsin I binds to the synaptic vesicle to the cytoskeleton. Calcium-dependent process 
known as synapsin I phosphorylation leads to the release of the vesicle from the cytoskeleton 
and then is transported into the active zone, where it binds to the presynaptic membrane [10]. 
The synaptic vesicle contains other important proteins; synaptobrevin and syntaxin on the 
presynaptic membrane act as shelter that pulls the membranes together. On the other hand, 
synaptosome-associated protein 25, which is attached to the presynaptic membrane, binds to 
two molecules of syntaxin, which forms a complex [11]. Synaptobrevin binds to this complex 
and displaces one of the syntaxin molecules from the complex, which brings the synaptic 
vesicle and the presynaptic membrane into the proximity that is necessary for fusion and 
exocytosis to take place [10].
From the above, we conclude that exocytosis is considered the primary mechanism for the 
release of acetylcholine, and this process is complicated and not fully investigated; however, 
it involved a lot of specific proteins. Therefore, any intervention with these proteins impaired 
acetylcholine release by exocytosis which results in presynaptic blocking, and this is what 
happens with BTX.
2. Mechanism of action of botulinum toxin
Botulinum neurotoxin is indeed a remarkable protein produced by Clostridium botulinum 
[12]; there are at least seven serotypes of neurotoxin discovered till now: botulinum toxin A 
(BTX-A), botulinum toxin B (BTX-B), botulinum toxin C (BTX-C), botulinum toxin D (BTX-D), 
botulinum toxin E (BTX-E), botulinum toxin F (BTX-F), and botulinum toxin G (BTX-G), only 
first two are medically used. Neurotoxins share with same target to inhibit presynaptic ace-
tylcholine release to synaptic cleft, but they are different in targeting protein, their duration 
of effect, and their potency [13, 14]. BTX-A displays their effect in relaxing the muscle propor-
tionally related to doses [15, 16].
The effect of BTX lasts for about 12–16 weeks; however, within 4 weeks soluble 
N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex of protein 
has its turnover. Exocytosis resumes and new axonal sprouting is at the end plate to reestab-
lish conduction [17].
2.1. Pharmacological aspects of botulinum toxin therapy
Botulinum toxin drugs currently available (BTX drugs) are Botox (Allergan Inc., Irvine, 
CA, USA), Dysport® (Ipsen Ltd., Slough, Berkshire, UK), NeuroBloc/Myobloc (Solstice 
Neurosciences Inc., Malvern, PA, USA), and Xeomin (Merz Pharmaceuticals, Frankfurt/M, 
Germany). From 1989 to 1992, Botox’s trade name was Oculinum®. In the USA and in some 
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other countries, NeuroBloc is distributed as Myobloc. Additional BTX drugs include Hengli 
(Lanzhou Institute of Biological Products, Lanzhou, Gansu Province, China), which is 
based upon BTX type A and which is distributed in some other Asian and South American 
markets as CBTX-A or Prosigne®, and Neuronox® (Medy-Tox, Ochang-eup, South Korea), 
which is sold in South Korea and in some other Asian countries. New BTX drugs are 
underdevelopment at Tokushima University, Tokushima City, Japan, and at the Mentor 
Corporation, Santa Barbara, CA, USA. Botox was the first BTX drug to be registered in 1989, 
while Dysport was registered in 1991, Hengli in 1993, NeuroBloc/Myobloc in 2000, and 
Xeomin in 2005.
Most of the currently available BTX drugs are shown in Figure 1. All BTX-A drugs are 
powders which need to be reconstituted with 0.9% NaCl/H2O prior to application. Only 
NeuroBloc/Myobloc is a ready-to-use solution. For all BTX drugs, special storage tempera-
tures are required. Xeomin is the only drug which can be stored at room temperature. The 
shelf lives of all BTX drugs are similar. The long shelf life of Xeomin is remarkable, since it 
was originally believed that the lack of complexing proteins would destabilize its BTX. Since 
NeuroBloc/Myobloc is stabilized by a reduced pH value, about half of the patients receiving 
NeuroBloc/Myobloc report intensified application pain.
2.2. Patient selection
The selection of CP patient who is a candidate for BTX-A application is based on clinical 
evaluation of spasticity, power, posture, gait, and other motions, rang of motion, and joint 
assessment whether dynamic or limited by contracture. Nevertheless, an accurate choice of 
the CP child for BTX-A might be difficult and need more complex assessment because of the 
dynamic character of spastic CP and must include motion [18].
Many studies adopted the relation between gait analysis assessment and clinical assessment; 
they found that both are complementary to each other in providing important information 
for planning the strategy of CP management. Therefore, observation of movement specially 
if combined with gait analysis data provides important information in selection of target 
muscles [19]. Assessment of motion at each joint with identification of spastic muscle that 
needs to be injected by BTX could be achieved by motion/gait analysis [20].
From these assessments, we conclude that motion analysis in the different anatomical posture 
for children while walking, crawling, sitting, rolling by physician, and videotaping is consid-
ered important in optimizing the benefits of BTX injection.
In nonambulatory CP child with Gross Motor Function Classification System [GMFCS] IV 
and V, x-rays are indicated in their regular follow-up, to rule out and develop hip dysplasia 
and scoliosis/kyphosis.
2.3. The use of botulinum toxin in cerebral palsy
There are many causes of cerebral palsy (CP) that make normal development of the limb 
without deformity and difficulty, but spasticity remains the most important cause as spastic 
muscle interferes with the neighboring bone and soft tissue growth, resulting in discrepancy 
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in growth between spastic muscle and other structures, with time of growing child dysmor-
phism and contracture of limb occurring with consequent loss of normal function with short-
ening of both the muscle and the limb if the tone is constantly remained hypertonic [21]. Such 
evidence of impairment of growth and deformity is also noted in animals with spasticity, 
for instance, spastic mouse [22]. Fortunately, stretching of the relaxed muscle may ensure no 
deformity and contracture with normal growth [23]. According to this hypothesis, it has been 
supposed that great benefit could be gotten from BTX from its action of relaxing the muscle in 
spastic CP, and this premise has been tested in mice with significant result regarding restor-
ing the muscle length to normal [24].
Figure 1. Some of the commercially available botulinum toxin drugs.
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Additional benefit from BTX injection to the hypertonic muscle enhances the reciprocal antag-
onist muscle to become stronger, with subsequent decrement of bone deformity as a result 
of decrease in discrepancy of impaired growth of spastic muscle and neighboring structure. 
Indeed, there is clear evidence of delay or decrease of the need for surgical intervention with 
injection of BTX specially if combined with other models of management such as physiother-
apy, casting, and orthotics. However, to achieve optimum goal of BTX injection, many factors 
are required, but the appropriate selection of the patient is the most important domain for the 
success of BTX injection. The patient should not have fixed contracture, and spastic patient 
with dynamic joint is considered typical for injection, whereas the patient with dyskinesia has 
mild to moderate effect. Athetoid types of CP usually do not get benefit [25].
Anyhow, management target is to progress normal sequence of milestone and attain the next 
motor development. The goal of treatment in ambulatory patient is to improve and optimize 
ambulation and walking [16]. Table 1 shows special indication.
2.4. Muscles of upper extremities
Many muscles in the upper limb are targeted by BTX injection. Again, selection of spastic 
muscle depends upon the patient’s state. Therefore, evaluation and assessment of the patient 
of proposed benefit functionally avoiding bone deformity are individualized according to the 
patient [26].
In the upper limb, the injection depends upon the spasticity pattern. For instance, spastic 
flexion of the elbow usually is in the brachioradialis muscle with or without biceps brachii 
muscle. For spastic forearm pronation injection will be in the pronator teres, while for spastic 
wrist flexion, the muscles involved with injections are flexor carpi radialis and flexor carpi 
ulnaris. Moreover, spastic flexion of the finger needs injection to flexor digitorum profun-
dus and superficialis, while adductor pollicis for the thumb commonly injected if the spastic 
thumb in the hand posture. The most common muscles injected for spastic shoulder defor-
mity are triceps brachii, pectoralis muscles, teres major, and deltoid [27].
Of note there is some time clinical modification which is individualized according to the 
patient. For instance, in elbow flexion maximum dose to brachioradialis muscle and mini-
mum or no injection of biceps brachii muscle to maintain function of arm in bearing things 
and in wrist spastic flexion maximum dose to flexor carpi ulnaris muscle if ulnar deviation of 
hand present. The injection of BTX should be done by an expert with well surface anatomi-
cal knowledge and choice large bulk of muscle with injection to near neural plate which is 
expected near to the mid-belly. Table 2 shows BTX injection of upper extremities.
2.5. Muscles of lower extremities
The lower limb muscle injection is considered the most important in spastic cerebral palsy 
via its benefit to decrease deformity and improve gait. The gastrocsoleus complex is consid-
ered the most common site of injection in dynamic toe-walking spastic CP patient, combined 
with injection to tibialis posterior for dynamic equinovarus deformity. These injections are 
considered typical in spastic diplegic CP and spastic hemiplegic CP. Other important lower 
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Indication/clinical pattern Goals Muscles involved Dose (U/kg) 
of BotoxR
Number of 
sites
Externally rotated shoulder Ease shoulder adduction Infraspinatus 1–2 1–2
Improving gait Teres minor 1 1
Enhance dressing Long head of triceps 2–3 2–3
Ease reaching Latissimus dorsi 1–4 2
Adducted/internally 
rotated shoulder
Ease shoulder abduction Pectoralis major 2 2–3
Improving gait Subscapularis 1 1–2
Enhance dressing (Teres major) 1 1
(Latissimus dorsi) 1–4 2
Flexed elbow Allow extension of the 
elbow
Biceps brachii 2–3 2–4
Enhance reaching Brachialis 2 1–2
Brachioradialis 1–2 1
Pronated forearm Allow supination Pronator teres 1 1
Improve dexterity Pronator quadratus 1 1
Flexed wrist Ease wrist extension Flexor carpi radialis 1–2 1
Ease wearing orthoses Flexor carpi ulnaris 1–2 1
Clenched fist/hand Improve hand opening Interosseous muscles 0.5–1 1
Improve wearing orthosis Lumbricalis muscles 0.5–1 1
Ease cleaning of the palm Flexor digitorum 
superficialis
1–2 1–4
Flexor digitorum profundus 1–2 1–4
Flexor pollicis longus 1–2 1–2
Thumb in the palm Enhance thumb abduction Adductor pollicis brevis 0.5–1 1
Help pinch and opposing Flexor pollicis brevis 0.5–1 1
Improve wearing orthosis Flexor pollicis longus 0.5–1 1
Ease hand opening Interosseous dorsalis I 0.5–1 1
Flexed hip Improving gait Iliacus/psoas 2–4 1–2
Crouch gait Enhance hip extension Rectus femoris 1–3 2
Stiff knee Improving swing phase by 
easing knee flexion
Rectus femoris 1–3 2
Scissoring gait, adducted 
thighs
Improve abduction and 
decrease scissoring gait
Adductor longus 1–4 1–2
Better perineal hygiene Adductor brevis 1–4 1–2
Ease wearing abductor 
braces
Adductor magnus 1–4 1–2
Improving sitting Gracilis 1–2 1–2
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limb BTX injections are semitendinosus and semimembranosus of hamstring muscles in order 
to decrease hypertonia of these muscles in dynamic knee joint with subsequent improve-
ment of the gait. Scissoring posture is one of the important problems in CP which also can 
markedly be decreased by BTX injection of adductor groups. Another muscle also injected in 
lower extremities is iliopsoas for spastic hip flexor; unfortunately, later on, it is difficult to be 
injected by palpation and needs technical equipment like ultrasound guidance for accurate 
injection [28, 29].
Muscles injected Dose range (IU/kg of bw) Number of sites
Adductor pollicis 0.5–1 1
Flexor pollicis longus 0.5–1 1
Flexor digitorum profundus 2 1–2
Flexor digitorum superficialis 2 1–2
Flexor carpi ulnaris 2 1
Flexor carpi radialis 2 1
Pronator teres 1 1
Biceps 2 2–3
Table 2. Muscle injected, dose, and number of injection of upper extremities [30].
Indication/clinical pattern Goals Muscles involved Dose (U/kg) 
of BotoxR
Number of 
sites
Flexed knee Improving balance and gait Semitendinosus 1–3 1–2
Crouch gait Enhance heel strike in 
stance
Semimembranosus 1–3 1–2
Ease sitting Biceps femoris 1–3 1–2
Gastrocnemius mediale/
laterale
3–6 1–4
Striatal toe Ease footwear Extensor hallucis longus 1–2 1
Toe clawing Improve balance and gait Flexor digitorum longus/
brevis
1–2 1
Prevent toe-turn Flexor hallucis longus 1–2 1
Equinovarus foot Improve plantar flexion Gastrocnemius mediale 1–3 1–2
Enhance heel strike in 
stance
Gastrocnemius laterale 1–3 1–2
Improving balance and gait Soleus 1–3 1–2
Ease wearing orthosis Tibialis posterior 1–2 1–2
Table 1. Indication, dose, target muscle, and number of injection [16, 30, 31].
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Although the primary goal of BTX injection to the lower limb is to improve ambulation in 
CP, BTX has an additional benefit; for example, injection of adductor and hamstring muscles 
may prevent progressive hip subluxation with positional improvement and decrease pain 
and stiffness, particularly when combined with bracing of the hip in abduction. Moreover, the 
benefits in nonambulatory patients may have improved pain and stiffness after injection and 
easy caring by relaxing adductor group. Table 3 shows BTX injection of lower extremities.
For optimizing relaxing effect of BTX-A, proposed high dose evolved. A lot of debate in last 
decade about safety of high dose of BTX-A. Generally, high doses adopted per injected muscle 
and multiple injections to many muscles in the same session have been used. The dosage of 
BTX-A per muscle depends on many factors including muscle bulk, degree of spasticity, and 
pathological pattern of the involved muscle. High dose of BTX-A is restricted to large muscle 
volume with sever spasticity. Many of spastic CP patients need multiple injections in same 
session to obtain maximum result [32].
The concept of high safe dose of BTX-A had been grown since the use of toxin. Initially, 
the toxin restricted for treatment of patient with focal spastic deformity is now widely used 
in multilevel therapy as the spastic CP patients have abnormal posture on multilevel of the 
musculoskeletal system; in consequence high dose is needed.
It is recommended to start with the lowest effective dose and increase with consequence injec-
tion depending on the previous session response and side effect. A wide range of total doses 
are found in review of literature, ranging from 2 to 29 U/kg/bw. As the initial use of BTX-A 
for equinus correction, the commonly referred dose range from 4 to 8 U/kg/bw can be found, 
while in the multilevel use of BTX-A, adopted higher dose with maximum doses ranged from 
10 to 29 U/kg/bw. A dose up to 40 U/kg/bw was used within multilevel injection of BTX-A. In 
one study [33]. Subsequent studies stated that high dose of BTX-A is safe to some extent. In 
review of literature with the multilevel use of BTX-A and multisite injection on monkeys, 
[34] conclude that there were no observable systematic effects at doses below 40 U/kg/bw 
(Table 4) [34].
Muscles injected Dose range (IU/kg of bw) Number of sites
Tibialis posterior 1–3 1
Soleus 2–3 1
Gastrocnemius 3–6 1–2
Adductors 3–6 2
Lateral hamstrings 2–3 2
Medial hamstrings 3–6 3–4
Quadriceps 3–6 4
Iliopsoas 2 2
Table 3. Muscle injected, dose, and number of injection of lower extremities [30].
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Of note, one has to put in his mind that the muscle like sponge principle pattern when exceed 
maximum contains fluid, leak from muscle could occur, and toxin enters the general blood 
circulation causing distant side effect which might be serious and life-threatening. That’s why 
we advise to use multisite theory, in which the dose has to be divided between more sites, 
with an up to a maximum of 25–50 U per site and not exceed in a volume of 1 ml per site, in 
addition to an inter-site distance of a minimum of 4–5 cm. As an interesting issue, for those 
who are obese, adjust the dose to the reference of their typical pairs with same age.
3. Postinjection BTX period
Although its maximum effect appears at 10 days to 4 weeks, the relaxing effect might start 
within 1–3 days and usually last for 3–6 months with exception of some patient for over a year 
called golden responder. Proper multidisciplinary team in terms of splinting, physiotherapy, 
and casting improve the outcome and increase golden responder patient numbers. Many 
centers adopt serial casting after significant relaxing effect of BTX that started and lasted for 
2–3 weeks after injections may optimize the benefit of injection [35].
3.1. How to localize muscles for botulinum toxin injection?
The child is not a small adult, generally uncooperative and sensitive to pain, and doesn’t like 
any technique that involves restriction of his movement for a long while. Therefore, invasive 
procedure like EMG is more difficult to be applied successfully in children than in adults.
3.2. Palpation
Palpation of the muscle, particularly for the large one, remains the cornerstone for injection of 
BTX in CP patient for most experts worldwide, but it needs a well of knowledge in anatomy 
and its landmark. If possible after injecting the needle to the target muscle belly by using ana-
tomic landmarks, palpation of the muscle, movement of distal joints that involve the target 
muscle, and then movement of injecting the needle confirm correct needle position.
In a study comparing manual needle injection and needle injection guided by electrical stimu-
lation, 226 spastic CP children are involved with 1372 separate injections for upper and lower 
extremity spasticity. A 27-gauge insulated Teflon-coated needle was used to stimulate the 
muscle and deliver BTX-A contraction of the target muscle without contraction of the neigh-
boring muscle. Then, needle position must be considered correct. The study concludes that 
Botox Dysport NeuroBloc/Myobloc
Range maximum dose/site (U) 10–50 50–250 Not established
Maximum total dose (U) 400 (−600) 500–1000 Not established
Range (U/kg bw) 1–20 (25) 1–20 (25) Not established
Table 4. Usual maximal dose of botulinum toxin preparation.
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needle placement guided by electrical stimulation is highly recommended for injections into 
small, slender, and deep-seated muscles, but dropout of such procedure needs cooperation 
which is difficult in children, so it is usually done by general anesthesia which could cause 
relaxing muscles and palpation of the target muscle become difficult [31].
BTX-A injections into 15 different muscles of 100 outpatients in cross-sectional study treat-
ment sessions were performed. All patients received combined analgesia and sedation with 
chloral hydrate prior to their BTX-A injections. Target muscles included small muscles of the 
forearm as well as large muscles of the lower extremity. Target muscles were identified based 
on anatomical palpation, and after the use of different tools, we conclude that injection of BTX 
with palpation results from significant improvement in ambulation [36].
3.3. EMG
There are two electrophysiological techniques to localize muscles: electromyography (EMG) 
and electrical stimulation [5, 37]. In a randomized, controlled clinical study, 28 patients with 
cervical dystonia received EMG-guided BTX-A compared with other patients using manual 
palpation-guided BTX injection. The study concludes that significant improvement to those 
patients that are guided by EMG for their BTX injection, specially patients with retrocollis, 
laterocollis, and shoulder elevation suggests great benefit from EMG-guided injection for 
deep cervical muscles [38] but unfortunately is inapplicable in spastic CP because EMG needs 
active and/or passive muscle stimulation for targeting muscles from neighboring muscles 
as long as spastic CP had difficulty to perform specific movements [39]. In addition needle 
EMG painful procedure limited its use in children; moreover, there is inaccurate correlation 
between the extent of spasticity in dystonia and the muscle activity detected by the EMG.
3.4. Electrical stimulation
Although electrical stimulation is considered an excellent procedure to localize the needle in 
the muscles [40], its use in children is imitated due to the localizing target muscle that needs 
multiple reposition of the needle which needs time and cause significant pain. Therefore, if elec-
trical stimulation is necessary, we need good analgesia with sedation; moreover, the effective 
use of electrical stimulation needs expert personal in neurophysiology and clinical anatomy.
3.5. Ultrasound
As an alternative to the above procedure, ultrasound is considered applicable and can directly 
visualize the muscle for injection. This procedure has been considered a successful method 
for anatomical muscle imaging, and there are many literatures concluding the use of ultra-
sound as a reliable technique for botulinum injection [41–43].
3.6. Evaluation and assessment of botulinum toxin injection in spastic 
cerebral palsy
The use of any parameter for assessment of post BTX-A injection based on the patient clinical 
situation for whom BTX-A indicated and what expected gain and accordingly appropriate 
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parameter tailored to patient, for instance, in nonambulatory patient, the usual goal to improve 
his care is by decreasing spasticity. Therefore, the choice measure to assess tone, while ambu-
latory patient we choice parameter that related to gait as our goal to improve his gait, etc. 
Therefore, the setting of evaluation, including pre- and postinjection of BTX-A is individual-
ized according to the goal of intervention; in addition to clinical examination, there are many 
tools used for this purpose, including the range of motion of the joints passively and actively; 
assessment of contractures by many tests, e.g., Thomas test, popliteal angle test, Silverskiöld 
test, and Duncan-Ely test; assessment of muscle power and imbalance, e.g., MRC, Janda, and 
Oxford scale; assessment of gait by gait analysis equipped by videotaping [44]; and goal attain-
ment scale (GAS) [45, 46]. Modified Ashworth Scale (MAS) is simple and reproducible in the 
assessment of muscle spasticity but is probably of limited validity [47, 48]. Modified Tardieu 
Rating Scale is more reliable and is focused on most clinically relevant parts of the Tardieu 
Scale [49, 50]. Gross Motor Function Measure (GMFM) is a validated tool for the measurement 
of motor function in children with CP [51, 52]. It may, however, not be sensitive enough to 
detect the minimal changes that occur following relatively minor interventions. Upper limb 
assessment tools, e.g., SHUEE and AHA scores or PEDI [53, 54], Activities Scale for Kids (ASK), 
only applicable to children aged 5–15 years [55], and gait analysis with three-dimensional 
assessment are extremely useful tools with objective analysis of gait before and after toxin 
injection and also useful in surgery intervention. Moreover, nowadays, the three-dimensional 
gait analysis became indispensable in clinical studies of gait [48, 56]. However, application of 
these assessment tools in everyday clinical practice may be limited by cost and availability.
Full detailed checklist for every child planned for BTX-A injection includes identity, goal of 
injection, last session date, side effect of the previous injection, muscles injected, doses, and 
assessment tools used.
3.7. Clinical decision of botulism toxin injection and its limitation
Spasticity is considered a positive phase of muscle function. Therefore, when relaxing the 
muscle, the patient might get worse functionally in some instance. So, the first question clini-
cian put in his account before injecting BTX is whether hypertonia is impeding or improv-
ing function. Another thing is that spasticity itself is associated with weakness and its high 
muscle tone may be a consequence to avoid involuntarily weakened muscle movement. For 
the time being no tools like EMG and gait analysis accurately provide obvious data related 
to hypertonia, and the clinical decision remains the cornerstone [57, 58]. Therefore, general 
functional and development assessment are considered the most important, while individual 
muscle assessment and using parameter, e.g., the Modified Ashworth Scale, Modified Tardieu 
Scale, or range of motion, are less important than general functional impairment assessment. 
As it is well known that spastic CP management needs a multidisciplinary team, hence it is 
crucial to determine the goal of management with periodic assessment for outcome with fre-
quent modification of treatment in order to tailor appropriate management to every patient.
Although there is general consensus that recovery from BTX-A injection is always complete 
and seems effective and safe, nevertheless there is no data till now about long-term effect and 
dropout. For that reason long-term studies are mandatory.
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BTX-A is a neurotoxin spread or injected to nontarget muscle that might cause further suf-
fering to the patients and therefore should be done by a well-trained personnel who familiar 
with BTX and muscle anatomy.
Many causes for inadequate outcome like false indication, incorrect injection, and lack of com-
plementary treatment (physiotherapy, occupational therapy, orthosis, etc.) are most common.
3.8. Adverse side effects of botulinum toxin
Generally, the adverse side effects of BTX-A are seldom to occur providing that the physi-
cian strictly adheres to the dose ranges and reinjection period [16]. The side effect may be 
local or distant from the injection site regarding local side effects, as with any intramuscular 
injection can cause pain, cause hematoma at the site of injection but usually not severe, and 
rarely cause significant problems. However, diffusion of BTX from the target injected muscle 
might cause weakness of neighboring muscles [28]. This is proportionally related to the vol-
ume of dilution; nevertheless, this diffusion is useful in injection of large muscle to optimize 
bulky muscle relaxation. Systemic side effects distant from injection site are rare and include 
double vision, dysphagia, generalized weakness of muscles, fluelike illness, constipation, and 
impaired bladder function, in CP patient with preexisting dysphagia. Further deterioration 
of bulbar muscle function might lead to aspiration pneumonia [28] which may be seriously 
life-threatening in such patient. Antibodies to botulinum toxin are found in some patients 
after several injections. The antibodies may be responsible for the tolerance to BTX developed 
by some patients [59, 60].
4. Conclusion
Botulinum toxin had established its significant role in management of spastic CP combined 
with other modalities of treatment. Most experts recommended it for use after 2 years of 
age for spasticity; in contrast untreated spasticity might lead to joint contracture, and the 
management may become difficult with multiple surgical interventions. Multilevel injection 
therapy is indicated to improve gait as most of spastic CP patients have multiple malposi-
tion of musculoskeletal system. The inter-injection period must be at least 12 weeks to avoid 
antibodies and ensure subsequent effect. So far, BTX-A is considered to be safe to some extent 
if used professionally; however, long-term adverse effect particularly with multilevel therapy 
is still not clear.
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